Mutabilis will present EBL-1463 at the 2021 BioInfect Conference Digital Event – Thursday 22nd April 2021 in the ‘What’s in the Pipeline – Part 1’ session. Title of the talk : Discovery of EBL-1463 a novel-class PBP inhibitor impervious to b-lactamase hydrolysis
READ MORECARB-X is awarding Mutabilis, a biopharmaceutical firm based in Romainville, France, up to US$6.4 million to develop a new drug to treat infections caused by Carbapenem-resistant Enterobacterales (CRE) bacteria. CRE has been dubbed the ‘nightmare bacteria’ by health officials because they cause deadly infections – often in healthcare settings – that cannot be effectively treated with existing antibiotics. Under the award agreement, Mutabilis will be eligible for an additional $5.8 million in further funding if certain project milestones are met, subject to available funds.
READ MORESeptember 2020. Due to the Covid-19 restrictions the 2020 AMR conference had to be held on the Internet this year. Within the session dedicated to the presentation of the IMI-ENABLE’s results, François Moreau, Mutabilis’ CSO, gave a presentation on EBL-1463. The presentation can be viewed here.
READ MOREJanuary 6th 2020: Novo Holdings REPAIR Impact fund announced a EUR 7 (USD 8) million investment in Mutabilis to accelerate its 2G Dabocins program
READ MORETitle of the talk : DISCOVERY OF DABOCINS, A NOVEL CLASS OF NON-BETA-LACTAM PBP INHIBITORS
READ MOREFollowing the integration of Mutabilis’ second programme in ENABLE in April 2018, the ENABLE Portfolio Management Committee has selected a candidate from this programme.
READ MOREMutabilis will be represented at the ASM MICROBE 2019 conference in San-Francisco from June 20th to 24th 2019.
READ MORELike last year, Mutabilis delegates will participate to the Berlin Conference on Novel Antimicrobials and Diagnosstics 2019 on March 14th – 15th 2019.
READ MOREThe World Health Organization had published earlier this year a list of the most concerning pathogens. The WHO continues with a report on the pipeline of antibiotics currently in clinical development to assess how we are going to manage the pathogens of the list.
READ MOREMutabilis has been selected by the European ENABLE project (European Gram-negative Antibacterial Engine), which aims to improve the development of antibiotics against infections caused by multiresistant Gram-negative bacteria.
READ MORE